Lani Hack

Lani Hack has been an engineer in the Antisense Oligonucleotide Formulation Development and Manufacturing group at Biogen since 2017. Her primary responsibilities are as a member of the drug delivery team directing the assessment of new delivery technologies to enhance the effectivity of oligonucleotide therapeutics for neurological indications. This work is driven through internal technical development initiatives and external collaborations.

In addition to her drug delivery work, Lani is responsible for the drug product development of candidate therapeutic molecules within the antisense oligonucleotide pipeline, from early-stage clinical trials through commercial life cycle management. She is also responsible for developing novel biophysical characterization methods to assess the physicochemical properties of oligonucleotides. Lani holds a bachelor’s degree in Chemical Engineering from the University of California, Berkeley.